Cardinal Health, Inc.

A rigorous stress test evaluates the vulnerability of Cardinal Health's razor-thin 1.03% operating margin ($2,613M operating income on $254.25B revenue in FY2026), to joint volume and pricing shocks. Customer concentration is acute: anchor pharmacy partner CVS Health generates 28% of revenue ($71.19B), while GPOs Vizient and Premier represent 29% ($73.73B). Precedent exists for major customer attrition, as evidenced by the departure of OptumRx in FY2024, which eliminated 17% of consolidated revenue. Under a stress scenario where CVS Health extracts a 10 bps fee concession and reallocates 20% of its volume, combined with 4% distribution center wage inflation and $3.3B in debt maturities refinancing into a 5.24% risk-free rate environment, consolidated operating margin compresses to 0.80%. Annual operating profit drops below $2.1B, cutting net income and driving diluted EPS toward $13.15 by FY2028, illustrating the sharp operating deleverage inherent in high-volume, low-margin wholesale distribution.

Narrow

Cardinal Health derives its competitive advantage from operating as an indispensable physical logistics backbone of the U.S. healthcare system. In fiscal 2026, the company generated $254.25B in consolidated revenue, distributing pharmaceuticals and medical supplies to healthcare providers across the country. Operating alongside McKesson and Cencora, Cardinal Health benefits from an entrenched wholesale triopoly that commands more than 90% of domestic drug distribution volume. This market concentration creates significant efficient scale, as the vast inventory requirements, specialized cold-chain infrastructure, and daily delivery schedules create high barriers to entry for prospective competitors.

The company's primary moat source is its route density and warehouse automation scale. In FY2026, capital expenditures were maintained at a disciplined $649M, representing approximately 0.26% of revenue, while continuous automation expansion drove total fill rates to nearly 99% and achieved historical records for on-time departures. Management has systematically eliminated operational bottlenecks to lower handling costs per unit, enabling Cardinal Health to profitably process hundreds of billions of dollars in pharmaceutical volume on an enterprise operating margin of 1.03% ($2,613M operating income).

Despite these formidable operational advantages, Cardinal Health's economic moat is rated Narrow rather than Wide due to extreme customer and intermediary concentration. Sales to anchor retail client CVS Health accounted for 28% of total revenue in FY2026, while sales through GPOs Vizient and Premier represented 29%. The historical loss of OptumRx in FY2024, which previously contributed 17% of revenue, confirms that large customers possess substantial bargaining leverage during contract renegotiations. This counter-leverage caps fee margins, bounding the firm's economic moat durability to a 10-year horizon (5 years explicit Stage I, 5 years Stage II fade).

Cardinal Health Inc. (CAH) trades at 17.7x forward earnings against a peer median of 16.7x. Its EV/EBITDA of 13.8x compares with a peer median of 14.6x. The comparison uses 4 peers: Cencora Inc., McKesson Corporation, Agilent Technologies Inc. and Boston Scientific Corporation, as of 2026-10-03.

Maintain a Hold rating on Cardinal Health Inc. (CAH). The stock trades at $228.30 as of 2026-10-02 against a composite intrinsic fair value of $244.05, offering 6.9% implied upside and a 6.5% discount to intrinsic value. At 17.7x forward earnings, the shares adequately reflect current distribution volume momentum, triopoly stability, and strong free cash flow ($4.53B in FY2026), while leaving an insufficient margin of safety for the 28% customer concentration with CVS Health.^4,6,8

Investors should maintain current holdings rather than deploying incremental capital. Cardinal Health functions as an indispensable logistics utility with reliable share repurchase accretion (diluted shares reduced to 237M), but enterprise upside is constrained by anchor customer bargaining leverage and thin 1.03% operating margins. A more compelling entry point would require a price discount toward $200-$210 or verifiable acceleration of specialty distribution operating margins toward 1.25%.